NSAIDs and Statins Have Chemopreventative Effects in Barrett's
December 08, 2011
The incidence of Barrett's esophagus and esophageal adenocarcinoma has increased despite surveillance of patients with Barrett's esophagus. Limited data indicate that NSAID and statin use reduce the risk for esophageal adenocarcinoma. Researchers from the Netherlands investigated whether NSAID or statin use reduces the risk of neoplastic progression from Barrett's esophagus. During a median follow-up period of five years, 7 percent of patients developed high-grade dysplasia or adenocarcinoma. After Barrett's esophagus had been diagnosed, 56 percent of patients used NSAIDs for a median duration of two months, 28 percent used aspirin for a median duration of five years, 37 percent used statins for a median duration of five years, and 19 percent used NSAIDs and statins. The team observed that NSAID and statin use were each associated with a reduced risk of neoplastic progression, and the use of a combination of NSAIDs and statins increased the protective effect.
0 out of 0 users found this page helpful.
Was this page helpful?
Only current members of the American Gastroenterological Association may post comments to this page.
Login To Comment
